Medallion Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$417K Sell
14,606
-737
-5% -$19.6K 0.13% 147
2026
Q2
$376K Sell
15,343
-2,449
-14% -$64.1K 0.12% 162
2026
Q1
$500K Buy
17,792
+1,346
+8% +$35.8K 0.16% 128
2025
Q4
$409K Sell
16,446
-231
-1% -$5.82K 0.14% 149
2025
Q3
$425K Sell
16,677
-954
-5% -$23.5K 0.15% 141
2025
Q2
$439K Buy
17,631
+1,098
+7% +$25.6K 0.17% 129
2025
Q1
$408K Buy
16,533
+2,230
+16% +$58.4K 0.19% 120
2024
Q4
$376K Buy
+14,303
New +$388K 0.19% 119

Other funds holding PFE

Medallion Wealth Advisors's PFE Position: Q3 2026 in Review

Medallion Wealth Advisors reduced its Pfizer (PFE) stake by 4.8% in Q3 2026, selling an estimated $19.6K and leaving 14,606 shares worth $417K. The position accounts for 0.13% of the portfolio, ranked #147.

Medallion Wealth Advisors first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. The position peaked at $500K in Q1 2026. 2,899 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Medallion Wealth Advisors held 14,606 shares of Pfizer worth $417K as of Q3 2026.
  • Medallion Wealth Advisors sold 737 Pfizer shares in Q3 2026, an estimated $19.6K.
  • Pfizer made up 0.13% of Medallion Wealth Advisors's portfolio in Q3 2026, its #147 holding.
  • Medallion Wealth Advisors first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
  • Medallion Wealth Advisors's Pfizer position peaked at $500K in Q1 2026.
  • 2,899 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Medallion Wealth Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.